Trial · NCT06244550
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 18 of 18
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Liver steatosis severity: the change of CAP (dB/m) by Fibroscan | Week 24 | The effect of once daily, oral administration of 500 mg/15 kg of body weight Ganwei and/or 1500 mg metformin 24 weeks treatment versus before on the change in Controlled Attenuation Parameter(CAP) by FibroScan |
| Primary | Liver fibrosis severity: the change of kPa by Fibroscan | Week 24 | The effect of once daily, oral administration of 500 mg/15 kg of body weight Ganwei and/or 1500 mg metformin 24 weeks treatment versus before on the change in kPa by FibroScan |
| Secondary | Aspartate Transaminase (AST) | Week 24 | The effect of once daily, oral administration of 500 mg/15 kg of body weight Ganwei and/or 1500 mg metformin 24 weeks treatment versus before on the change in Aspartate Transaminase (AST) |
| Secondary | Alanine amino Transferase (ALT) | Week 24 | The effect of once daily, oral administration of 500 mg/15 kg of body weight Ganwei and/or 1500 mg metformin 24 weeks treatment versus before on the change in Alanine amino Transferase (ALT) |
| Secondary | Body mass index (BMI) | Week 24 | The effect of once daily, oral administration of 500 mg/15 kg of body weight Ganwei and/or 1500 mg metformin 24 weeks treatment versus before on the change in Body mass index (BMI) |
| Secondary | Glycated Hemoglobin (HbA1c) | Week 24 | The effect of once daily, oral administration of 500 mg/15 kg of body weight Ganwei and/or 1500 mg metformin 24 weeks treatment versus before on the change in Glycated Hemoglobin (HbA1c) |
| Secondary | White blood cell (WBC) | Week 24 | The effect of once daily, oral administration of 500 mg/15 kg of body weight Ganwei and/or 1500 mg metformin 24 weeks treatment versus before on the change in White blood cell (WBC) |
| Secondary | C-reactive protein (CRP) | Week 24 | The effect of once daily, oral administration of 500 mg/15 kg of body weight Ganwei and/or 1500 mg metformin 24 weeks treatment versus before on the change in C-reactive protein (CRP) |
| Secondary | Triglyceride (TG) | Week 24 | The effect of once daily, oral administration of 500 mg/15 kg of body weight Ganwei and/or 1500 mg metformin 24 weeks treatment versus before on the change in Triglyceride (TG) |
| Secondary | estimated Glomerular filtration rate (eGFR) | Week 24 | The effect of once daily, oral administration of 500 mg/15 kg of body weight Ganwei and/or 1500 mg metformin 24 weeks treatment versus before on the change in estimated Glomerular filtration rate (eGFR) |
| Secondary | Physical functioning | Week 24 | The effect of once daily, oral administration of 500 mg/15 kg of body weight Ganwei and/or 1500 mg metformin 24 weeks treatment versus before on the change in Physical functioning by 36-Item Short Form Health Survey (SF-36) |
| Secondary | Role limitations due to physical health | Week 24 | The effect of once daily, oral administration of 500 mg/15 kg of body weight Ganwei and/or 1500 mg metformin 24 weeks treatment versus before on the change in Role limitations due to physical health by 36-Item Short Form Health Survey (SF-36) |
| Secondary | Role limitations due to emotional problems | Week 24 | The effect of once daily, oral administration of 500 mg/15 kg of body weight Ganwei and/or 1500 mg metformin 24 weeks treatment versus before on the change in Role limitations due to emotional problems by 36-Item Short Form Health Survey (SF-36) |
| Secondary | Energy/fatigue | Week 24 | The effect of once daily, oral administration of 500 mg/15 kg of body weight Ganwei and/or 1500 mg metformin 24 weeks treatment versus before on the change in Energy/fatigue by 36-Item Short Form Health Survey (SF-36) |
| Secondary | Emotional well-being | Week 24 | The effect of once daily, oral administration of 500 mg/15 kg of body weight Ganwei and/or 1500 mg metformin 24 weeks treatment versus before on the change in Emotional well-being by 36-Item Short Form Health Survey (SF-36) |
| Secondary | Social functioning | Week 24 | The effect of once daily, oral administration of 500 mg/15 kg of body weight Ganwei and/or 1500 mg metformin 24 weeks treatment versus before on the change in Social functioning by 36-Item Short Form Health Survey (SF-36) |
| Secondary | Bodily pain | Week 24 | The effect of once daily, oral administration of 500 mg/15 kg of body weight Ganwei and/or 1500 mg metformin 24 weeks treatment versus before on the change in Pain by 36-Item Short Form Health Survey (SF-36) |
| Secondary | General health | Week 24 | The effect of once daily, oral administration of 500 mg/15 kg of body weight Ganwei and/or 1500 mg metformin 24 weeks treatment versus before on the change in General health by 36-Item Short Form Health Survey (SF-36) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06244550/registered